Pregled bibliografske jedinice broj: 1250389
Croatian guidelines for the diagnosis and treatment of nonalcoholic fatty liver disease
Croatian guidelines for the diagnosis and treatment of nonalcoholic fatty liver disease // Acta clinica Croatica, 60 (2021), Suppl 2; 36-52 doi:10.20471/acc.2021.60.s1.03 (međunarodna recenzija, pregledni rad, znanstveni)
CROSBI ID: 1250389 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Croatian guidelines for the diagnosis and treatment of nonalcoholic fatty liver disease
Autori
Virović Jukić, Lucija ; Grgurević, Ivica ; Mikolašević, Ivana ; Filipec Kanižaj, Tajana ; Milić, Sandra ; Mrzljak, Anna ; Premužić, Marina ; Hrstić, Irena ; Knežević Štromar, Ivana ; Ljubičić, Neven ; Ostojić, Rajko ; Stojsavljević Shapeski, Sanja ; Amerl-Šakić, Vjekoslava ; Bašić Marković, Nina ; Rađa, Marko ; Soldo, Dragan ; Sobočan, Nikola ; Lalovac, Miloš ; Puljiz, Željko ; Podrug, Kristian ; Ladić, Dinko
Izvornik
Acta clinica Croatica (0353-9466) 60
(2021), Suppl 2;
36-52
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, pregledni rad, znanstveni
Ključne riječi
nonalcoholic fatty liver disease (NAFLD) ; nonalcoholic steatohepatitis (NASH) ; metabolic syndrome ; screening ; noninvasive methods ; hepatocellular carcinoma
Sažetak
Nonalcoholic fatty liver disease (NAFLD) is a term describing excessive accumulation of fat in hepatocytes, and is associated with metabolic syndrome and insulin resistance. NAFLD prevalence is on increase and goes in parallel with the increasing prevalence of metabolic syndrome and its components. That is why Croatian guidelines have been developed, which cover the screening protocol for patients with NAFLD risk factors, and the recommended diagnostic work-up and treatment of NAFLD patients. NAFLD screening should be done in patients with type 2 diabetes mellitus, or persons with two or more risk factors as part of metabolic screening, and is carried out by noninvasive laboratory and imaging methods used to detect fibrosis. Patient work-up should exclude the existence of other causes of liver injury and determine the stage of fibrosis as the most important factor in disease prognosis. Patients with initial stages of fibrosis continue to be monitored at the primary healthcare level with the management of metabolic risk factors, dietary measures, and increased physical activity. Patients with advanced fibrosis should be referred to a gastroenterologist/ hepatologist for further treatment, monitoring, and detection and management of complications
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Farmaceutsko-biokemijski fakultet, Zagreb,
Klinička bolnica "Merkur",
Medicinski fakultet, Rijeka,
Stomatološki fakultet, Zagreb,
Medicinski fakultet, Zagreb,
Klinički bolnički centar Osijek,
KBC "Sestre Milosrdnice",
KBC Split,
Opća bolnica Pula,
Klinička bolnica "Dubrava",
Klinički bolnički centar Zagreb,
Medicinski fakultet, Split,
Klinički bolnički centar Rijeka
Profili:
Željko Puljiz
(autor)
Ivana Mikolašević
(autor)
IVANA KNEŽEVIĆ ŠTROMAR
(autor)
Miloš Lalovac
(autor)
Neven Ljubičić
(autor)
Lucija Virović Jukić
(autor)
Nikola Sobočan
(autor)
Anna Mrzljak
(autor)
Marko Rađa
(autor)
Rajko Ostojić
(autor)
Irena Hrstić
(autor)
Dragan Soldo
(autor)
Nina Bašić-Marković
(autor)
Tajana Filipec Kanižaj
(autor)
Ivica Grgurević
(autor)
Sandra Milić
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE